Impact of SARS-CoV-2 infection in patients with cystic fibrosis in Spain: Incidence and results of the national CF-COVID19-Spain survey - 22/08/20
, Esther Quintana-Gallego c, d, Rosa M. Giron-Moreno e, Isidoro Cortell-Aznar f, Marta Ruiz de Valbuena-Maiz g, Layla Diab-Caceres h, Concepcion Prados-Sanchez i, Antonio Alvarez-Fernandez j, k, Patricia W. Garcia-Marcos a, Carlos Peñalver-Mellado l, M. Dolores Pastor-Vivero m, Casilda Olveira n, o, Alejandro Lopez-Neyra p, Silvia Castillo-Corullon q, Samara Palma-Milla r, Estela Perez-Ruiz n, s, Amparo Sole-Jover t, M. Isabel Barrio g, Manuel Sanchez-Solis a, b, u, Óscar Asensio de la Cruz v, won behalf of
CF-COVID19-Spain Registry Group
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Abstract |
Background |
Given the high incidence of confirmed infection by SARS-CoV-2 and mortality by COVID-19 in the Spanish population, its impact was analysed among persons with Cystic Fibrosis (CF) as a group at risk of a worse evolution. The possible causes of the incidence observed in them are explained and how CF Units have faced this health challenge is detailed.
Methods |
Retrospective descriptive observational study, for which a Spanish CF Patients with Confirmed COVID-19 Registry is created, requesting information on number of people affected between 8 March–16 May 2020 and their clinical-demographic characteristics from the CF Units participating in the European Cystic Fibrosis Society Patient Registry (ECFSPR). The accumulated incidence is calculated, compared with that of the general population. Additionally, a survey (CF-COVID19-Spain) is carried out on prevention of SARS-CoV-2 infection, workings of CF Units and possible reasons for the incidence observed.
Results |
COVID-19 was diagnosed in eight CF patients, one of whom had received a lung transplant. The accumulated incidence was 32/10000 in CF patients and 49/10000 in the general population. General death rate was 5.85/10000 while no CF patients included in the ECFSPR died. The characteristics of those affected and the results of the survey are described.
Conclusions |
Despite being considered a disease at high risk of severe COVID-19, the low incidence and mortality in CF patients in Spain contrasts with the figures for the general population. The possible factors that would explain such findings are discussed, with the help of the results of the CF-COVID19-Spain survey.
Le texte complet de cet article est disponible en PDF.Highlights |
• | SARS-CoV-2 pandemic is severely hitting Spain. |
• | Cumulative incidence among Spanish CF patients is being lower than expected. |
• | No fatal cases were reported in our CF patients with COVID-19 included in ECFSPR. |
• | CF-COVID19-Spain survey was useful to explain its low incidence and mild course. |
Keywords : Cystic fibrosis, SARS-CoV-2, Coronavirus, COVID-19
Plan
Vol 170
Article 106062- août 2020 Retour au numéro
Article précédent
- BPI-ANCA is expressed in the airways of cystic fibrosis patients and correlates to platelet numbers and Pseudomonas aeruginosa colonization
- Gisela Hovold, Ulrika Lindberg, Johanna K. Ljungberg, Oonagh Shannon, Lisa I. Påhlman
- Phenotypic and molecular characteristics of CF patients carrying the I1234V mutation
- Bat El Bar Aluma, Ifat Sarouk, Hanoch Senderowitz, Malena Cohen-Cymberknoh, Netaly Khazanov, Adi Dagan, Yael Bezalel, Moshe Ashkenazi, Shlomit Keler, Ori Efrati
Bienvenue sur EM-consulte, la référence des professionnels de santé.